NCT06039384View on ClinicalTrials.gov

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

April 11, 2025

Study Completion Date

July 11, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

INCB099280

Administered as specified in the treatment arm description

DRUG

adagrasib

Administered as specified in the treatment arm description

Trial Locations (14)

10060

Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo

20089

Irccs Istituto Clinico Humanitas, Rozzano

22042

Inova Schar Cancer Institute, Falls Church

28223

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón

37124

Centro Ricerche Cliniche Di Verona (Crc), Verona

41009

Hospital Universitario Virgen Macarena, Seville

48202

Henry Ford Health System, Detroit

75251

Mary Crowley Cancer Research Centers McCrc Headquarters, Dallas

80631

Banner Md Anderson Cancer Center, Greeley

90067

Valkyrie Clinical Trials, Los Angeles

08023

Hospital Hm Nou Delfos, Barcelona

08035

Hospital General Universitario Vall D Hebron, Barcelona

SE1 9RT

Guys Hospital, London

W12 0HS

Hammersmith Hospital, London

Sponsors

Lead Sponsor

Incyte Corporation

Collaborators (1)

Mirati Therapeutics Inc.
All Listed Sponsors
collaborator

Mirati Therapeutics Inc.

INDUSTRY

lead

Incyte Corporation

INDUSTRY

NCT06039384 - A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Biotech Hunter | Biotech Hunter